SCHEMBL1437217

SCHEMBL1437217

Cc1ccc(Cl)cc1-n1c(-c2ccccn2)nc(C(=O)O)c1-c1cccc(Cl)c1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 5/20 0.80
PDE4B Q07343 1/20 0.43
PDE4D Q08499 1/20 0.43
KDM4C Q9H3R0 1/20 0.42
PIN1 Q13526 1/20 0.42
DCTPP1 Q9H773 1/20 0.41
PTGER1 P34995 1/20 0.41
KMO O15229 1/20 0.41
CNR2 P34972 1/20 0.41
TP53 P04637 3/20 0.41
POLB P06746 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
NPC1 O15118 1/20 0.39
MITF O75030 1/20 0.39
MAPT P10636 1/20 0.39
PKM P14618 1/20 0.39
TSHR P16473 1/20 0.39
GRM5 P41594 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1443425 0.90 MDM2 (1.00) MDM2PIN1TP53PKMGRM5
SCHEMBL9893974 0.89 MDM2 (0.63) MDM2PDE4BPDE4DTP53L3MBTL1
SCHEMBL9893709 0.88 MDM2 (0.80) MDM2PDE4BPDE4DKDM4CPIN1
SCHEMBL27862799 0.85 MDM2 (0.85) MDM2PIN1TP53MAPTPKM
SCHEMBL1436973 0.84 MDM2 (0.89) MDM2PIN1TP53POLBMAPT
SCHEMBL9893927 0.84 MDM2 (1.00) MDM2PIN1TP53POLBMAPT
SCHEMBL1437137 0.83 MDM2 (0.87) MDM2PDE4BPDE4DPIN1TP53
Dimethylformamide SCHEMBL27879047 0.83 MDM2 (0.86) MDM2PIN1PKMSMN1; SMN2
SCHEMBL9894197 0.83 MDM2 (0.82) MDM2PDE4BPDE4DPIN1TP53
SCHEMBL1437181 0.83 MDM2 (0.55) MDM2PDE4BPDE4DPTGER1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2470502-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS Novartis AG (CH) 2012-07-04 EP disclosed
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2012-06-14 US disclosed
WO-2011023677-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2011-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS MDM4, MDM2, TP53 MDM2 2/4885PDE4B 3755/4885PDE4D 3804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.